Last reviewed · How we verify
Placebo + Prolonged Imaginal Exposure
Placebo combined with prolonged imaginal exposure therapy leverages psychological habituation to trauma memories through repeated, extended mental reliving of traumatic events.
Placebo combined with prolonged imaginal exposure therapy leverages psychological habituation to trauma memories through repeated, extended mental reliving of traumatic events. Used for Post-traumatic stress disorder (PTSD).
At a glance
| Generic name | Placebo + Prolonged Imaginal Exposure |
|---|---|
| Sponsor | Weill Medical College of Cornell University |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Mental Health |
| Phase | Phase 3 |
Mechanism of action
Prolonged imaginal exposure is a cognitive-behavioral psychotherapy technique in which patients repeatedly and vividly recall traumatic memories in a safe therapeutic setting, allowing emotional processing and habituation to fear-related memories. The placebo component may enhance therapeutic expectancy and engagement. This combination is used to treat post-traumatic stress disorder (PTSD) by reducing avoidance behaviors and emotional reactivity to trauma-related cues.
Approved indications
- Post-traumatic stress disorder (PTSD)
Common side effects
- Temporary increase in anxiety or distress during exposure sessions
- Emotional exhaustion
- Nightmares or sleep disturbance
Key clinical trials
- Estrogen and Fear in PTSD (PHASE3)
- MDMA-Assisted Massed Exposure Therapy for PTSD (PHASE2)
- MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder (PHASE2)
- Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer (PHASE3)
- Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine (PHASE2)
- Cortisol Augmentation of a Psychological Treatment in Warfighters With Post Traumatic Stress Disorder (PTSD) (NA)
- Cortisol Augmentation of Prolonged Exposure Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: